Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
biotech deals
Biotech
Contineum-J&J drug fails to improve vision in phase 2 MS trial
The Johnson & Johnson-partnered asset failed to trigger any significant change in vision acuity for MS patients.
Gabrielle Masson
Nov 20, 2025 5:26pm
GSK picks 1st biotech partners under $7B Flagship pact
Nov 20, 2025 6:30am
Merck KGaA becomes latest partner for Flagship’s Valo Health
Nov 20, 2025 6:30am
Tempest strikes all-stock deal for Factor’s CAR-T pipeline, CEO
Nov 19, 2025 12:22pm
J&J pays $3B cash for Halda's cancer cell death tech
Nov 17, 2025 10:19am
AbbVie to end Calico collab, lay off scientists: Stat
Nov 13, 2025 3:59pm
